The preclinical drug screening of pancreatic cancer treatments suffers from the absence of
appropriate models capable to reproduce in vitro the heterogeneous tumor …

Microfluidic devices as translational research tools provide a potential alternative to animal
experiments due to their ability to mimic physiological parameters. Several approaches that …

The dense cancer microenvironment is a significant barrier that limits the penetration of
anticancer agents, thereby restraining the efficacy of molecular and nanoscale cancer …

With advances in underlying technologies such as complex multicellular systems, synthetic
materials, and bioengineering techniques, we can now generate in vitro miniaturized human …

Despite untiring efforts to develop therapies for pancreatic ductal adenocarcinoma (PDAC),
survival statistics remain dismal, necessitating distinct approaches. Photodynamic priming …

To improve the prognosis of glioblastoma, innovative radiotherapy regimens are required to
augment the effect of tolerable radiation doses while sparing surrounding tissues. In this …

The complex interplay between cancer cells and their microenvironment remains a major
challenge in the design and optimization of treatment strategies for pancreatic ductal …

The current standard preclinical oncology models are not able to fully recapitulate
therapeutic targets and clinically relevant disease biology, evidenced by the 90% attrition …

Chemoradiation therapy is on the forefront of pancreatic cancer care, and there is a
continued effort to improve its safety and efficacy. Liposomes are widely used to improve …

A key reason for the persistently grim statistics associated with metastatic ovarian cancer is
resistance to conventional agents, including platinum-based chemotherapies. A major …